Collagen type I degradation biomarkers are associated with risk of mortality after ST-elevated myocardial infarction.

Emily Martin^{1,2*}, Elisavet Angeli^{1,2}, Federica Genovese², Morten Karsdal², Martin Frydland³, Jacob Eifer Møller^{4,5}, Christian Hassager^{3,6}

¹Nordic Bioscience, Denmark, ²Institute of Biomedical Sciences, University of Copenhagen, Denmark, ³Department of Cardiology, Copenhagen University Hospital, Denmark, ⁴Research Unit for Cardiology, Odense University Hospital, Denmark.

PURPOSE

After ST-elevated myocardial infarction (STEMI), collagen type-I (COLI), the myocardium's main constituent, is acutely degraded from cardiac tissue. **Destabilisation** of the cardiac tissue by extracellular matrix remodelling post-STEMI could increase the risk of further adverse events.


We aimed to quantify COLI using specific plasma biomarkers, including a novel signalling fragment of COL1 (CISIG) and a more established **COLI degradation** marker (CIM).

We also evaluated their use in risk prediction for all-cause

METHODS

The novel ELISA-based biomarker targeting a signalling fragment of COLI (CISIG) was technically developed and evaluated before measuring in the plasma of 1,616 verified STEMI patients. The plasma COLI degradation marker, CIM, was measured in all STEMI patients.


	Overall (n=1,616)
Sex (male)	73.0%
Age (years)	64.0 [19] Median [IQR]
CIM (ng/ml)	20.7 [10.6] Median [IQR]




mortality after STEMI event.


C1SIG (ng/ml)	30.4 [9.50] Median [IQR]
Death (n)	100 / 136 (30 / 365 days)

RESULTS




High C1M and high C1SIG, as the highest quartile and above the median, respectively, were independently and significantly associated with all-cause mortality in verified STEMI patients at 1-year post-admission. C1M and C1SIG are risk predictors for all-cause mortality at 1-year post-STEMI in univariate and multivariate cox regression analysis when adjusted for a model based on the Framingham score. Model 1 was based on the Framingham Score (age, sex, diastolic blood pressure (BP), systolic BP, hypercholesterolemia, diabetes, smoking) and time to blood sampling. Model 2 was model 1 plus clinically used and emerging cardiac biomarkers (mid-





DOES CIM OR CISIG ADD VALUE TO THE FRAMINGHAM RISK SCORE?

The likelihood ratio test statistic suggests that CIM and CISIG independently (but also together) improve the fit of the Framingham risk score. Other analyses may support



some added value C1M biomarker to the

Framingham score.

CONCLUSION

C1M and C1SIG are independently prognostic for mortality in STEMI patients after 1 year, in a multivariate model based on the Framingham Score. Assessing acute extracellular matrix processing in STEMI patients using COLI biomarkers could be beneficial for predicting mortality and identifying a patient subset at increased risk of long-term outcome.

Disclosures: EM, EA, FG, and MK are employed by and are shareholders of Nordic Bioscience. **Funding**: The research is funded by the European Union's Horizon Europe Marie Skłodowska-Curie Actions Doctoral Networks–Industrial Doctorates Programme (HORIZON–MSCA–2021–DN-ID), grant number 101072828. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or Marie Sklodowska-Curie Actions. Neither the European Union nor the granting authority can be held responsible for them.

